



**Lakeridge  
Health**

# Welcome

Lakeridge Health Surgical Update for Primary  
Care Physicians

Oct. 16<sup>th</sup> 2014

# Housekeeping Items

- Please ensure that all mobile devices are **off** or **silent**
- Your audience response device can be used to provide anonymous responses to any question asked throughout this event.
- Parking exit passes (provided to all participants) can be used directly at the parking exit gates (re-insert the pass you obtained when entering our parking facility, followed by insertion of the exit the pass provided at this event).





**Lakeridge  
Health**



**Queen's**  
UNIVERSITY

# **Surgical Update Lung Cancer- From Suspicion to Treatment**

Dr. Shannon Trainor

Thursday October 16<sup>th</sup> 2014

# Objectives

- Presentation of Lung Cancer
- Work up/evaluation
- Central East Thoracic Surgery Diagnostic Assessment Program (DAP)
- Brief Overview Management of Lung Cancer
- VATS Lobectomy
- Future- Screening






## Question #1:

In Ontario, Deaths from Lung Cancer exceed deaths by any other cancer cause.

- ✓ A. True
- B. False




## Question # 2:

Approximately 1 in 12 Canadian men and 1 in 20 Canadian women are expected to develop lung cancer during their lifetime.

A. True

✓ B. False



# Burden of Disease- Statistics


- It is estimated that in 2014:
  - 26,100 Canadians will be diagnosed with lung cancer. This represents 14% of all new cancer cases in 2014.
  - 20,500 Canadians will die from lung cancer. This represents 27% of all cancer deaths in 2014.
  - On average, 72 Canadians will be diagnosed with lung cancer every day.
  - On average, 56 Canadians will die from lung cancer every day.

Canadian Cancer Society Statistics 2014



# Burden of Disease

Percentage of All Estimated New Cancer Cases in Both Sexes Combined in 2014



Percentage of All Estimated Cancer Deaths in Both Sexes Combined in 2014



# Risk Factors

- Cigarette smoking
  - 2<sup>nd</sup> hand smoke exposure
- Asbestos exposure
- Radon exposure
- Chronic inflammation
- Pulmonary fibrosis (IPF)
- Personal or Family History of Lung Cancer
- Exposure To radiation



# Relative Risk of Lung Cancer

## Smoking Category

## Relative Risk

- |                       |        |
|-----------------------|--------|
| • Never smokers       | • 1.0  |
| • Current Smokers     | • 15   |
| • Former Smokers      |        |
| • Years of abstinence |        |
| • <10                 | • 5-15 |
| • 10-20               | • 2-6  |
| • >20                 | • 2-4  |



# Presentation

- Asymptomatic (i.e... Often found on X-rays done for another purpose)
  - Will become less frequent as CXR not done as routine pre-op
- Local symptoms
  - Broncho-pulmonary
  - Non broncho-pulmonary
- Symptoms from Metastatic Disease
- Paraneoplastic Syndromes



# Presentation

- Local- Broncho-pulmonary Symptoms:
  - Cough is most common symptom (50-70%)
    - Worsens or non resolving
  - Hemoptysis
  - Wheezing or stridor (from airway obstruction)
  - Dyspnea
  - Post obstructive infectious symptoms





# Presentation

- Local- Non Broncho-pulmonary Symptoms:
  - Pain
  - Pancoast Syndrome ( ipsilateral Horner's, pain and muscular atrophy of the arm and hand)
  - Dysphagia
  - Hoarseness
  - Superior Vena Cava Syndrome (swollen face, conjunctival hemorrhage, brain edema)
  - Symptoms from pleural or pericardial effusions



# Presentation

- Symptoms From Metastatic Disease:
  - Most common site is brain, bone, liver and adrenal glands
  - Bone metastases often cause pain or pathologic fractures
  - 20% of patients have bone metastases on presentation
  - Brain metastases can cause headache, blurred vision, nausea and changes in mental status
  - Adrenal mets are usually asymptomatic
  - Liver mets are also usually asymptomatic until late in the disease
  - Palpable adenopathy



# Presentation

- Symptoms from Para-neoplastic Syndromes:
  - The production of secretory products that invoke immune response on distant end-organs
  - May present even before lung masses are visible on imaging studies
  - Most often associated with small cell or squamous cell ca
  - 2% of lung cancer
  - Hypercalcemia, SIADH (hyponatremia), anemia, peripheral neuropathy, clubbing



**Table 96-1. Intrathoracic Signs and Symptoms of Lung Cancer**

Cough	29–87%
Hemoptysis	9–57%
Chest pain	6–60%
Dyspnea	3–58%
Wheezing or stridor	2–14%
Hoarseness	1–18%
Pleural effusion	7%
Dysphagia	2%
Superior vena cava syndrome	4–11%
Pancoast's syndrome	3–5%
Phrenic nerve paralysis	1%

Data from Chute et al. (1985), Hyde and Hyde (1974), Rahim and Sarma (1984), Lam et al. (1983), Hopwood et al. (1995), Cohen (1974), LeRoux (1968), and Chernow and Sahn (1977).



**Paraneoplastic Syndromes Associated with Lung Cancer†****Systemic**

Anorexia, cachexia, weight loss\*  
Fever  
Orthostatic hypotension  
Nonbacterial thrombotic endocarditis  
Dermatomyositis/polymyositis  
Systemic lupus erythematosus

**Cutaneous**

Acquired hypertrichosis lanuginosa  
Acrokeratosis (Bazex's syndrome)  
Clubbing\*  
Dermatomyositis  
Erythema gyratum repens  
Exfoliative dermatitis  
Hypertrophic pulmonary osteoarthropathy  
Superficial thrombophlebitis\*  
Tripe palms  
Acanthosis nigricans  
Acquired ichthyosis  
Acquired palmoplantar keratoderma  
Erythema annulare centrifugum  
Florid cutaneous papillomatosis  
Pemphigus vulgaris  
Pityriasis rotunda  
Pruritus  
Sign of Leser-Trelat  
Sweet's syndrome  
Vasculitis

**Renal**

Glomerulopathies  
Tubulointerstitial disorders

**Endocrine/metabolic**

Cushing's syndrome  
Hypercalcemia\*  
Hyponatremia\*  
Hyperglycemia  
Hypertension  
Acromegaly  
Hyperthyroidism  
Hypercalcitoninemia  
Gynecomastia  
Galactorrhea  
Carcinoid syndrome  
Hypoglycemia  
Hypophosphatemia  
Lactic acidosis  
Hypouricemia  
Hyperamylasemia

**Hematologic**

Anemia\*  
Polycythemia  
Hypercoagulability  
Thrombocytopenic purpura  
Dysproteinemia (including amyloidosis)  
Leukocytosis/Leukoerythroblastic reaction  
Eosinophilia

**Neurologic**

Peripheral neuropathy\*  
Lambert-Eaton myasthenic syndrome\*  
Neurotizing myelopathy  
Cerebral encephalopathy  
Visual loss  
Visceral neuropathy

†Modified from Patel, AM, Jett, JR, Clinical presentation and staging of lung cancer. In: Comprehensive Textbook of Thoracic Oncology, Aisner, J, Arrigada, R, Green, MR, et al (Eds), Williams & Wilkins, Baltimore, 1996, p. 293.

\* Indicates more common paraneoplastic syndromes




# Imaging


- Chest X-ray:
  - Often initial imaging
  - Inexpensive and easy access
  - Poor detail for staging
- CT Scan:
  - Provides details regarding features of a pulmonary nodule/mass
  - Assess regional lymphadenopathy
  - Some assessment of the abdominal solid organs
  - Does not provide a tissue diagnosis



# Imaging



# Imaging






# Your Most Important Role!

- Suspicion Leads to Imaging
- Biggest issue is delay in diagnosis
- Referral for Evaluation
- Centralized Referral Process for Thoracic Surgery
- Call us if concerns any time



# Central East Thoracic DAP: Triage Process



## \* **Priority 1:**

New or suspicious for malignancy and acutely symptomatic with...

Wait time goal: 5 business days or next available

## **Priority 2:**

New or suspicious for malignancy but not acutely symptomatic (see above)

Wait time goal: 1-2 weeks or next available

## **Priority 3:**

Known treated malignancy

Wait time goal: 2-3 weeks or next available

## **Priority 4:**

Benign disease

Wait time goal: 28 days or next available

# CE Thoracic Surgery Process Flow

**Regional Clinics  
(Scar/Peterborough/DRCC)**

## *Pre-Op Phase*

### Pre-Post & investigations

- Nurse Navigator Surgical consult & decision-making
- Dx: lab, DI, pathology
- Pulmonary Function
- Interventional radiology
- Endoscopy
- Specialist oncology consults
- Psychosocial support
- Surgery for benign disease (TBD)
- Pathology

GP referral (1-800)

**Consolidated Thoracic Surgical Service  
(Lakeridge Health)**

## *Operative/Therapeutic Phase*

### Pre-op

- Anesthesia prep
- Dx: lab, DI

### OR

- All surgery for intra thoracic malignancies (lung, esophagus, pleura, mediastinum)
- Surgery for benign disease (TBD)
- Pathology

### Post-op

- PACU
- Dx: lab, DI

### Inpatient

- ICU
- Inpatient bed
- Dx: Lab, DI

**Regional Clinics  
(Scar/Peterborough/DRCC)**

## *Post-Op Phase*

### Post-op Follow-up

- Clinic visit with Nurse Navigator Surgeon
- Post-op dx

### Rehab / CCAC

- Post-op rehab and/or home care/personal supports


Coverage by thoracic surgeons and multidisciplinary teams – common standards

Care Coordination with Integrated Network (includes Systemic / Radiation Therapy / Oncology resources)

Integrated PACS and Laboratory IS

Integrated OR booking system - standardize


# DAU: Active Coordination Navigation Model



# Work Up

- Review Imaging
  - Need details of tumor/nodule itself (size, location)
  - Assess the mediastinum
  - Rule out distant disease
- Full bloodwork
- Physical Examination
- Determine means to obtain a diagnosis
- Discuss smoking cessation
- Staging
- Determination of Treatment





# Suspicion of Cancer

- Nodule is more likely to be cancer when:
  - Size:
    - larger size or known increase in size
  - Age increases
  - Smoking history
  - Spiculated appearance
  - upper lobe location
  - Patient history malignancy
  - PET positive



# Follow up of Pulmonary Nodules

## Recommendations for Follow-up and Management of Nodules Smaller than 8 mm Detected Incidentally at Nonscreening CT

Nodule Size (mm)*	Low-Risk Patient†	High-Risk Patient‡
≤4	No follow-up needed§	Follow-up CT at 12 mo; if unchanged, no further follow-up
>4–6	Follow-up CT at 12 mo; if unchanged, no further follow-up	Initial follow-up CT at 6–12 mo then at 18–24 mo if no change
>6–8	Initial follow-up CT at 6–12 mo then at 18–24 mo if no change	Initial follow-up CT at 3–6 mo then at 9–12 and 24 mo if no change
>8	Follow-up CT at around 3, 9, and 24 mo, dynamic contrast-enhanced CT, PET, and/or biopsy	Same as for low-risk patient

Note.—Newly detected indeterminate nodule in persons 35 years of age or older.

\* Average of length and width.

† Minimal or absent history of smoking and of other known risk factors.

‡ History of smoking or of other known risk factors.

§ The risk of malignancy in this category (<1%) is substantially less than that in a baseline CT scan of an asymptomatic smoker.

|| Nonsolid (ground-glass) or partly solid nodules may require longer follow-up to exclude indolent adenocarcinoma.





# Question #3


- What is the most accurate means to obtain a tissue diagnosis in a peripheral stage 1 lung cancer?
  1. sputum cytology
  2. bronchoscopy
  3. ct guided FNA biopsy
  4. diagnostic wedge resection



### Question #3:

What is the most accurate means to obtain a tissue diagnosis in a peripheral stage 1 lung cancer?

- A. Sputum cytology
- B. Bronchoscopy
- C. CT guided FNA biopsy
- ✓ D. Diagnostic wedge resection



# Diagnosis

- How do we determine diagnosis of malignancy (tissue) or work up a tumor?
  - Sputum cytology
  - Bronchoscopy
  - Fine Needle Aspiration of Nodes
  - Needle Biopsy (typically CT scan guided)
  - Mediastinoscopy/ EBUS
  - Surgery
    - Pleuroscopy
    - Diagnostic wedge resection




# Bronchoscopy

- May provide a diagnosis by tissue biopsy if there is an endobronchial component or by washings
- Helps determine resectability with tumors in the proximal airway
- Can allow palliation thru stents and lasers
- Low yield for peripheral tumours




# Percutaneous Needle Biopsy




- Typically CT guided
- Core biopsy preferred
  - Diagnosis now not just cancer vs benign disease
  - NSCLC vs SCLC
  - Chemotherapy treatment is more sophisticated
  - Adeno vs squamous
  - EGFR and ALK mutation testing

# Pleuroscopy


- Direct Assessment of the Pleural Space
- Pleural Nodularity or effusion
- Thoracentesis alone yields diagnosis 50-60%
- Cytology and pleural biopsy diagnostic yield is >95%
- Allows for diagnosis but also fusion of the pleural space:
  - Talc pleurodesis
  - Indwelling pleurex catheter



# Mediastinoscopy



- Invasive staging of mediastinal lymph nodes
- Obtains a diagnosis
- Staging to rule out N2 or N3 disease
- Facilitates good tissue for mutation testing etc.
- All patients with tumors >3cm, central lesions or PET Avid nodes



#### Superior Mediastinal Nodes

- 1 Highest Mediastinal
- 2 Upper Paratracheal
- 3 Pre-vascular and Retrotracheal
- 4 Lower Paratracheal (including Azygos Nodes)

#### Aortic Nodes



- 5 Subaortic (A-P window)
- 6 Para-aortic (ascending aorta or phrenic)

#### Inferior Mediastinal Nodes


- 7 Subcarinal
- 8 Paraesophageal (below carina)
- 9 Pulmonary Ligament

#### N1 Nodes

- 10 Hilar
- 11 Interlobar
- 12 Lobar
- 13 Segmental
- 14 Subsegmental



A



B



Lakeridge  
Health



# TNM Staging: T = Tumor

- T1: < 3 cm; no structures invaded
- T2: > 3 cm but less than 7 cm; involvement of visceral pleura and more than 2 cm from the carina
- T3: > 7cm,invading chest wall, < 2 cm from carina
- T4: invading unresectable structures, carina, malignant effusion or satellite tumor

# TMN- Nodal Status

- N0
- N1- ipsilateral intrapulmonary nodes or hilar nodes
- N2- ipsilateral mediastinal or subcarinal nodes
- N3- contralateral, scalene or supraclavicular nodes

# TMN- Metastases

- Distant Metastases (M)
  - Mx presence of distant metastases cannot be assessed
  - M0 no distant metastases
  - M1 distant metastases present

## TNM staging system for lung cancer (7th edition)

Primary tumor (T)			
T1	Tumor ≤3 cm diameter, surrounded by lung or visceral pleura, without invasion more proximal than lobar bronchus*		
T1a	Tumor ≤2 cm in diameter		
T1b	Tumor >2 cm but ≤3 cm in diameter		
T2	Tumor >3 cm but ≤7 cm, or tumor with any of the following features:		
	Involves main bronchus, ≥2 cm distal to carina		
	Invades visceral pleura		
	Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung		
T2a	Tumor >3 cm but ≤5 cm		
T2b	Tumor >5 cm but ≤7 cm		
T3	Tumor >7 cm or any of the following:		
	Directly invades any of the following: chest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium, main bronchus <2 cm from carina (without involvement of carina)		
	Atelectasis or obstructive pneumonitis of the entire lung		
	Separate tumor nodules in the same lobe		
T4	Tumor of any size that invades the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, or with separate tumor nodules in a different ipsilateral lobe		
Regional lymph nodes (N)			
N0	No regional lymph node metastases		
N1	Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension		
N2	Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)		
N3	Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)		
Distant metastasis (M)			
M0	No distant metastasis		
M1	Distant metastasis		
M1a	Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural or pericardial effusion		
M1b	Distant metastasis (in extrathoracic organs)		
Stage groupings			
Stage IA	T1a-T1b	N0	M0
Stage IB	T2a	N0	M0
Stage IIA	T1a,T1b,T2a	N1	M0
	T2b	N0	M0
Stage IIB	T2b	N1	M0
	T3	N0	M0
Stage IIIA	T1a,T1b,T2a,T2b	N2	M0
	T3	N1,N2	M0
	T4	N0,N1	M0
Stage IIIB	T4	N2	M0
	Any T	N3	M0
Stage IV	Any T	Any N	M1a or M1b

\* The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.

Adapted from: Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groups in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2:706.



# Staging

- PET Scan
  - Done in the absence of metastatic disease
  - Stages the mediastinal nodes and distant disease
  - 14% of the time picks up metastases not detected by other modalities
  - Does not evaluate the brain
- MRI Brain
  - Done in patients with tumors >clinical stage 1
  - Any symptomatic patients
- Physiologic Work up
  - Pulmonary function
  - Selective cardiac tests





# Staging

- If advanced disease on presentation
  - Bone scan
  - MRI brain
  - Or as directed to symptoms
- Referral to medical/radiation oncology
- No physiologic work up




# Staging



# Staging – PET Scan

- Nuclear medicine scan
- Utilizes different rates of glucose metabolism in different tissues
  - $^{18}\text{F}$ FDG (fluorodeoxyglucose) injection
- SUV (standard uptake value) helps determine malignancy
- PET-CT provides anatomic detail, improves diagnostic accuracy





# Physiologic Evaluation


- Key information on history regarding exercise tolerance
  - Flights of stairs
- All candidates for surgery have pulmonary function
- Echo should be done if considering pneumonectomy
- Cardiac evaluation as required
- If borderline,  $FEV_1 < 60\%$  ,  $DLCO < 60\%$  may need
  - Exercise testing to determine  $VO_2$  Max
  - Post op predicted numbers must be 30-40%



## Question #4:

### Surgery is:

- ✓ A. Superior to focused radiation (SBRT) for local control and staging
- B. Only for stage 1 tumors
- C. A thoracotomy always
- D. Not safe after chemotherapy and/or radiation



# Treatment:



**Surgery** the first choice

**Chemotherapy**  
Or  
**Radiotherapy**  
A distant  
second choice



# Non Surgical Therapy

- SBRT
  - Stereotactic body radiation treatment
  - Fractionated dosing in few treatments
  - accomplished by using multiple beams (typically 10 to 12)
  - Goal is to minimize damage to surrounding lung tissue
  - Local control approx. 90%




# Role of Surgery

- Gold Standard of Treatment
- All patients with early stage disease
  - Stage 1 and 2
- Stage 3 disease (ipsilateral nodal mets)
  - Induction chemoradiation
    - Young patients
    - Non bulky nodal disease
- Pancoast/Superior Sulcus Tumors
  - Induction chemoradiation followed by surgery


## *No Surgery*

- Bulky Stage 3a disease
- Stage 3 b disease
- Stage 4 disease
  - except palliation of symptoms
  - le. effusions


# Surgery- Resections




Lobectomy



Pneumonectomy



Wedge Resection



Segmentectomy

# Thoracotomy







Figure 1 Diagram showing the line of skin incision.



# VATS







# Equipment



# VATS LOBECTOMY- Potential Advantages of Compared to Thoracotomy

- Reduced surgical trauma
- Decreased postoperative pain
- Faster return to full activity
- Shorter chest tube duration
- Shorter length of stay
- Preserved pulmonary function
- Superior cosmetic result
- Improved delivery of adjuvant therapy

# VATS Lobectomy- Ideal



# VATS Lobectomy- Not Ideal



# Complications of Pulmonary Surgery

- Death
  - Lobectomy 1-2 %
  - Pneumonectomy 2-4%
- Pulmonary complications: PE, pneumonia, atelectasis
- Cardiac Complications: most common a fib
- Wound infection
- Bleeding
- Prolonged airleak
- Empyema 2-15% Post thoracotomy chronic pain

# Follow up

- We follow our patients quite closely
- Q3months for 2 years
- Then q6month for 1 years
- Then yearly for 5 years total
- CXR, history and physical examination
- Annual CT scan
- Done for detection of metastases from their resected tumour
  - Also risk of developing 2<sup>nd</sup> malignancy
  - Approx. 2% per year




# Adjuvant Therapy

- Stage IB  $\geq$  4cm – consider adjuvant chemo
- N1 or N2 Disease
- Incomplete Resection



# 5 year survival- 17%

## Overall survival by TNM grouping, non-small cell lung cancer



Overall survival, expressed as median survival time (MST) and five-year survival, using the seventh edition of TNM staging system by (A) clinical stage and (B) pathologic stage.

Reproduced with permission from: Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007; 2:706. Copyright © 2007 Lippincott Williams & Wilkins.



# Question #5


With respect to screening for lung cancer:

1. It should be done on all smokers
2. A CXR is adequate
3. Has been shown to decrease lung cancer deaths
4. Is widely implemented in Canada

## Question #5:

With respect to screening for lung cancer:

- A. It should be done on all smokers
- B. It should be done on all smokers
- ✓ C. Has been shown to decrease lung cancer deaths
- D. Is widely implemented in Canada



# Future- Screening

- National Lung Screening Trial
  - annual low-dose CT screening
  - in patients with a 30 pack-year history of smoking
  - including those who quit smoking in the preceding 15 years,
  - demonstrated a decrease in lung cancer and all-cause mortality
  - relative reduction in the rate of death from lung cancer of 20.0%

# Future- Screening

## **Cancer Care Ontario Guidelines**

### **Recommendation :**

Screening for lung cancer with LDCT is recommended in high-risk populations defined as persons 55 to 74 years of age with a minimum smoking history of  $\geq 30$  pack-years\* who currently smoke or have quit within the past 15 years and are disease free at the time of screening.





**"Are you sure this is the only way  
the nicotine patch will work for you?!"**



**Lakeridge  
Health**

# Thank You

# References

- Up to Date
- Fleishner Society Guidelines 2013 for management of Solitary Pulmonary Nodules



Lakeridge  
Health



Queen's  
UNIVERSITY

## Surgical Update

# Common Hand Injuries

For Primary Care Physicians

Dr. Alexander Golger

Plastic Surgeon

OCTOBER 16, 2014




# Introduction

Injuries of the hands are a common reason for visits to primary care clinics and emergency departments, comprising approximately 10% of all admissions.

A series of 1,000 consecutive hand injuries showed the following distribution: 42% lacerations, 27% contusions, 17% fractures, and 5% infections. Hand injuries account for about 17% of all workday loss injuries.

To care for such injuries well and communicate the extent of the injuries to the specialist, clinicians must have a sound grasp of basic hand anatomy.




## Joints:

Distal inter phalangeal (DIP)  
Proximal inter phalangeal (PIP)  
Metacarpal Phalangeal (MCP/MP)  
Carpometacarpal (CMC)


## Thumb:

Inter phalangeal (IP)  
Metacarpal Phalangeal (MCP/MP)  
Basal/Carpometacarpal


# INTRINSIC MUSCLES OF THE HAND




# POSTERIOR COMPARTMENT OF THE FOREARM




Posterior views




# ANTERIOR COMPATMENT OF THE FOREARM



# NEUROVASCULAR ANATOMY OF THE PALM







# Question 1






## Question #1:

Which of the fingers FDP is completely lacerated?

- A. Middle Finger
- B. Ring Finger
- C. Little Finger
- D. None of the above



## Question 2:




## Question #2:

What would be the appropriate emergency room treatment for the deep laceration?



- A. Explore the wound, repair injured structures, refer to a plastic surgeon
- B. Irrigate the wound, close the laceration, if no functional losses, arrange for suture removal with family doctor
- C. Explore the wound, call plastic surgeon on call for emergency surgery
- D. Call plastic surgeon stat to ER



## Question 3:





## Question #3:

What is the appropriate treatment for the above injury?



- A. AlumaFoam splint as needed
- B. AlumaFoam splint X 6 weeks 24/7
- C. Basic DIP splint X 6 - 8 weeks 24/7
- D. Stack splint X 2 – 3 weeks until healed



# HAND LACERATIONS


## Taking relevant history

- Dominant hand, occupation, immunization, comorbidities, meds, allergies
- Mechanism of injury
- Time of the injury
- Precise side and site of the injury

# Mechanism of injury



# Mechanism of injury





# Mechanism of injury



# Physical Examination

## Observation

Location of the laceration, hand or finger posture, swelling, color, erythema, compared to opposite hand

# Physical Examination

## Observation



# Physical Examination

Based on functional anatomy




# Physical Examination

Based on functional anatomy



# Physical Examination

Based on functional anatomy



Sharp/Dull and Two point discrimination can be quickly Assessed with a paper clip



# Physical Examination

Based on functional anatomy

Allen's test




Capillary refill test





# Flexor Tendon Injuries

		Fingers	Thumb	Significance
Location:	Zone I	FDP insertion to FDS insertion	At FPL insertion	Good outcome
	II	FDS insertion to proximal A1 pulley	FPL insertion to proximal A1 pulley	Worse outcome ("no man's land")
	III	A1 pulley to carpal tunnel	Within thenar compartment	Good outcome
	IV	Within Carpal tunnel	Within Carpal tunnel	Variable outcome
	V	Proximal to carpal tunnel	Proximal to carpal tunnel	Excellent outcome (except spaghetti wrist)
Extent:	Complete			
	Incomplete			
Type:	Laceration			
	Avulsion			
	Rupture			





# Flexor Tendon Injuries

Timing of Surgical Treatment			
	Time course	Advantage/Disadvantage	Indications/contraindications
Primary	within 24 hrs	Not necessary, may not be optimal	Contraindications: <ul style="list-style-type: none"> <li>• Severe, multi-level injury §</li> <li>• Contamination - esp human bite</li> <li>• Significant skin/soft tissue loss §</li> <li>• Unstable fractures not rigidly fixed</li> <li>• Unrepairable pulley system §</li> <li>• Concomitant injuries/medical condition</li> </ul>
Delayed primary	up to 2 weeks	Best option - yields equivalent or better results than primary	Contraindications: <ul style="list-style-type: none"> <li>• Unstable fractures not rigidly fixed</li> <li>• Active infection</li> <li>• Unstable soft tissue §</li> </ul>
Secondary:	Early	2 - 5 weeks	Comparable outcome <ul style="list-style-type: none"> <li>• May be undertaken as soon as skin heals &amp; joints regain PROM</li> </ul>
	Late	> 5 weeks	Worse outcome - due to muscle shortening & tendon end resorption <ul style="list-style-type: none"> <li>Indications: <ul style="list-style-type: none"> <li>• Late presentation</li> <li>• Other injuries</li> <li>• Pre-existing finger deformities (eg flexion contracture)</li> </ul> </li> </ul>




§ Probably relative indications

# Flexor Tendon Avulsion (Jersey finger)





- Avulsion of FDP at its insertion is a common, mostly athletic injury (contact sports)
- Mechanism is *forced extension* of the FDP during *maximal contraction*
- Ring FDP is involved in ~75% of cases
- Males > Females

# Flexor Tendon Avulsion (Jersey finger)

Type		Tendon position	Significance	
I	Both vincula ruptured	Tendon end retracts to palm	Repair within 7-10 days before significant contraction & tendon ischemia set in	
II	Long vinculum intact	Tendon retracts to PIP with or without small bone fragment	Less devascularization and shortening - late primary repair possible	
III	Fracture-avulsion	Tendon held up at A4 pulley by bone fragment	ORIF required	
IV (Smith)	Fracture of P3 with avulsion of FDP from bone fragment	Tendon retracts to palm	ORIF + tendon reinsertion required	

# Extensor tendons injuries



# Extensor tendons injuries

## **Zone I**

Running stitch which incorporates both tendon and skin  
(dermatotenodesis)

## **Zone II**

Core type suture difficult to use because of tendon thickness  
Running stitch and cross stitch

## **Zone III - V**

Core suture – modified Kessler or Bunnell – 4.0 or 5.0  
nonabsorbable braided suture with a small tapered needle to  
prevent shredding of the thin flat tendon

Epitendinous suture – cross stitch – dorsal surface only – 5.0  
nonabsorbable monofilament


# Extensor tendons injuries

Zone 1 Extensor injury – **Mallet** finger deformity



# Extensor tendons injuries

## Mechanism of mallet finger injury



Mallet finger occurs most commonly during a direct blow to the tip of the finger, such as when a ball strikes the fingertip or the fingertip strikes a rigid surface

Less frequently, a mallet finger may occur as part of finger injuries involving dorsal lacerations or crushing mechanisms

# Extensor tendons injuries - Mallet

Type I closed blunt trauma leads to loss of tendon continuity with or without a small avulsion fracture (most common)

Type II laceration at or proximal to the DIPJ with loss of tendon continuity

Type III deep abrasion with loss of skin, subcutaneous tissue and tendon substance

Type IVA Salter-Harris type II injury

Type IVB articular surface fracture involving 20-50% joint surface

Type IVC articular surface fracture  $> 50\%$  and early or late volar subluxation of the distal phalanx



# Extensor tendons injuries (mallet finger)

**INDICATIONS FOR REFERRAL** — The majority of mallet finger injuries can be managed by primary care clinicians, but more complex injuries warrant evaluation by a hand surgeon. Commonly accepted indications for surgical referral include:

- Inability to achieve full passive extension of the DIP joint
- Full laceration of the extensor tendon
- Volar (palmar) subluxation of the distal phalanx
- Fracture involving greater than 30 percent of the joint surface

# Extensor tendons injuries

## Treatment (mallet finger)



- splint can be applied to either the palmar or dorsal surface of the middle and distal phalanx .
- the splint should be bent slightly to stabilize the DIP joint in 5 to 10 degrees of hyperextension
- Immobilize DIP in full continuous extension for 6 - 8 weeks (24/7)

# Fingertip Injuries


## Definition

Portion of digit distal to insertion of flexor and extensor tendons

## Epidemiology


Almost half of all hand injuries presenting to the ER involve the fingertip

Middle fingertip most likely to be injured, followed by ring, index, little, thumb (longest to shortest)



# Fingertip Injuries

## Allen's classification



# Fingertip Injuries

## Management

- Analgesic  $\pm$  local anaesthetic
- Tetanus prophylaxis
- X-ray
- Wound I&D
- Prophylactic antibiotics (grossly contaminated, immunocompromised, diabetic)
- Wound closure - technique depends on:
  - pattern of skin & pulp loss
  - bone - covered vs. exposed; fractures
  - nailbed injuries - level, severity

# Fingertip Injuries

## Management

- Composite graft
- Secondary healing
- Bony shortening and secondary healing or primary closure
- Skin graft
- Local / regional flaps
- Free flap

# Fingertip Injuries

## Management

### Composite grafting of amputated tip

- Greatest success distal to lunula, small children
- Alternatively, reapply to defatted skin as full thickness skin graft

*Advantages:* preservation of length, cosmetics

*Disadvantages:* poor survival; decreased sensation

# Fingertip Injuries

## Management

### **Primary closure**

Absorbable or non-absorbable suture

***Advantages:*** Faster healing time and less wound care than secondary healing; better sensation than skin graft or flap

***Disadvantages:*** May be difficult to perform without excessive tension; may lead to hook nail deformity if nail bed drawn over fingertip; sensory function no better than healing by secondary intention



# Fingertip Injuries

## Management

### **Secondary healing**

Daily cleansing of tip with warm, soapy water, then apply bandage and polysporin

***Advantages:*** Better sensation than skin grafts or flaps because as wound contracts innervated glabrous skin covers part of fingertip; rapid; inexpensive; no donor morbidity; no risk joint contracture or other iatrogenic injury (c.f. local flaps)

***Disadvantages:*** Prolonged healing may delay return to work; potential sensitivity or unstable scar if insufficient bony padding

# Fingertip Injuries



# Fingertip Injuries



# Fingertip Injuries

**Therapy:** Once wound is healed, may require tip desensitization therapy, ROM exercises, Coban wrapping if swollen

**Outcome:**

- healing usually within 3-6 weeks
- manual labourers generally return to full duties within 6-8 weeks

**Sequelae of injury** (regardless of treatment approach):

- cold sensitivity
- dysesthesias, hyperesthesias
- numbness
- painful neuroma



Thank you  
Questions please



**Lakeridge  
Health**

# **21 Questions! Rotator cuff disorders and Osteoarthritis**


Samir Chhabra

Orthopedic Surgeon Lakeridge Health

## Question:

These are poor prognostic signs for a surgical repair of rotator cuff tears:

- A. Age above 70 years
- B. Large rotator cuff tears
- C. Muscle atrophy
- D. Proximal migration of humeral head
- ✓ E. All of the above



# Rotator Cuff Disorders

## Objectives:

- Clinical Evaluation
- Role of X-rays, Ultrasound and MRI
- Management



# Q.1 Who suffers from rotator cuff disorders?

- Age group – middle age onwards

# Q2. Symptoms and signs?

## History

- Pain – laterally, upper third arm. Night pain
- Weakness

## Examination:

- Atrophy
- Range
- Power



# Power testing of the rotator cuff



# Power testing of the rotator cuff




# Power testing of the rotator cuff



# Q3. Which investigation should I order?

- X-rays
- Ultrasound
- MRI

# X-Ray



# USG

- Advantages
  - a. Non- invasive
  - b. When MRI is contraindicated
  - c. Readily available
  - d. No wait time!!
- Disadvantages
  - a. Operator dependent
  - b. Not as sensitive and specific as the MRI

Probably its use is as a screening tool



# MRI

Not for all patients !

- Elderly ( Physiologically 70 – 75 years ).
- Differentiate between frozen shoulder and rotator cuff disorders

## Q4. How do I treat rotator cuff disorders?

Conservative:

- Analgesics and anti-inflammatories
- Physiotherapy
- Corticosteroid injections

# Q5. What is role of surgery ?

Traumatic – with or without shoulder dislocation

Failure of conservative management.


Rotator cuff tears in the elderly- don't do well with repairs – consider reverse shoulder arthroplasty

# Q.6 Types of surgery?

Arthroscopic repairs

Mini open repairs


Tendon transfers



## Question:

Validated options for conservative management of Osteoarthritis includes all of these modalities EXCEPT:

- A. Aerobic exercises
- B. Weight reduction
- ✓ C. Sodium hyaluronate injections
- D. Antinflammatory medications



# Osteoarthritis of knees /hips

## Observations:

- Occurring in younger patients
- Patients living longer – a major problem in the elderly
- Expectations from reconstruction/ replacement

# **Q7. Conservative management – Exercises?**

## **Do they work ?**

Low impact aerobic exercises

Aquatic exercises

Self management programs

# Aerobic exercises

Aerobic	Muscle-Strengthening
<ul style="list-style-type: none"><li>• Walking</li><li>• Dancing</li><li>• Swimming</li><li>• Water aerobics</li><li>• Jogging</li><li>• Aerobic exercise classes</li><li>• Bicycle riding (stationary or on a path)</li><li>• Some activities of gardening, such as raking and pushing a lawn mower</li><li>• Tennis</li><li>• Golf (without a cart)</li></ul>	<ul style="list-style-type: none"><li>• Exercises using exercise bands, weight machines, hand-held weights</li><li>• Calisthenic exercises (body weight provides resistance to movement)</li><li>• Digging, lifting, and carrying as part of gardening</li><li>• Carrying groceries</li><li>• Some yoga exercises</li><li>• Some Tai chi exercises</li></ul>



# Q7. Conservative management – weight loss? Does it work ?

WEIGHT LOSS if BMI > 25


# **Q8. Conservative management – Acupuncture? Does it work ?**

Acupuncture- Existing evidence shows that it does not work

# Q9. Conservative management – Physical agents? Do they work ?

TENS, Short wave diathermy, Ultrasound – results are inconsistent

# Q10. Conservative management – Massages? Do they work ?



# Q11. Conservative management – Braces and Orthotics? Do they work ?

Unloader brace- inconclusive

lateral wedge insoles for patients with symptomatic medial compartment osteoarthritis of the knee – **Does not work!!**

## Q12. Conservative management –Chondrotin and glucosamine? Do they work ?



# Q14. Conservative management – Hyaluronic acid? Do it work ?

## Sodium Hyaluronate

# Q14. Conservative management – Hyaluronic acid? Do it work ?



Sodium Hyaluronate




# Q15. Conservative management – Corticosteroid injections? Do they work ?

Inconclusive

Similarly with platelet rich plasma

# Q16. Operative management –Arthroscopic lavage? Does it work ?



NO- DOES NOT WORK!!

Only if mechanical symptoms such as locking or giving way, then may help

# Q17. Operative management –Tibial Osteotomies ? Do they work ?



Limited evidence

# Q18. Operative management –Arthroplasty-hips

Probably the most successful operation

Stood the test of time

Survival improving with less complications

Types- metal on plastic, metal on ceramic, metal on metal

# Q18. Operative management –Arthroplasty- hips Role of various types

Commonest- metal on plastic

Younger patients- Metal on Ceramic



# Q.19 Role of Metal on Metal hip replacements

Young male < 65 yrs

Large frame

Surgeon well versed with  
the procedure

Aware of complications: pseudotumours / fractures



# Q20. Total knee replacements?

Good operation

Results not as great as one would expect

Takes quite a while to get better


About 10-15% dissatisfaction rate

Certainly motivation to get better plays a BIG ROLE in getting a good result!!

## Question:

Orthopedic services to the community physicians can be improved maximally by:

- A. Single form Referral sheet
- B. Shorter wait time for consultation
- C. Shorter wait time for surgery
- D. Availability of specialist opinion via phone or text/email during office hours







Lakeridge  
Health



COVIDIEN

*positive results for life™*

ETHICON

PART OF THE *Johnson & Johnson* FAMILY OF COMPANIES

Better surgery  
for a better world

# Thank-You



Lakeridge  
Health



Queen's  
UNIVERSITY

# Thank-You

Presentation materials will be made available at [www.lhearnsurgery.ca](http://www.lhearnsurgery.ca)

**Next event: April 30<sup>th</sup> 2014**

Potential future topics:

- **General Surgery**
- **Orthopedic Surgery**
- **Plastic Surgery**
- **Ophthalmology**
- **Otolaryngology**

- **Thoracic Surgery**
- **Urology**
- **Anesthesia**
- **Obstetrics and Gynaecology**

Visit <https://events.lakeridgehealth.on.ca/> for early online registration

*\* Note: Please return your audience response device at the registration desk*



**Lakeridge  
Health**